SCHEMBL6318564

SCHEMBL6318564

Cc1cccc(CNC(=O)c2c(-c3ccc(Cl)o3)noc2N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA7 P43166 1/20 0.50
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 1/20 0.46
MMP13 P45452 1/20 0.45
KMT2A Q03164 2/20 0.45
ADORA2A P29274 4/20 0.44
ADORA1 P30542 3/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2B P29275 1/20 0.44
ATM Q13315 1/20 0.43
GAA P10253 1/20 0.42
PTGS1 P23219 2/20 0.42
GHSR Q92847 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314500 0.90 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL6323008 0.90 CA1 (0.52) CA1CA2CA4CA7HPGD
SCHEMBL6322856 0.88 CA1 (0.50) CA1CA2CA4CA7ALDH1A1
SCHEMBL6318222 0.88 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL6324100 0.88 CA1 (0.53) CA1CA2CA4CA7ALDH1A1
SCHEMBL6323666 0.87 CA1 (0.55) CA1CA2CA4CA7ALDH1A1
SCHEMBL6316256 0.85 MEN1 (0.50) CA1CA2CA4CA7HPGD
SCHEMBL6318351 0.84 PTPN22 (0.46) ALDH1A1HPGDMAPTKMT2AADORA2A
SCHEMBL6317749 0.84 ADORA2A (0.60) ALDH1A1KDM4EHPGDHSD17B10MMP13
SCHEMBL6317315 0.83 CA1 (0.51) CA1CA2CA4CA7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 CA1 2406/4885CA2 2764/4885CA4 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.